Women have a natural protection that gives them greater longevity. One hypothesis most commonly used is the estrogen protection in the premenopausal period. However many studies of various forms of hormone replacement therapy proved ineffective in promoting additional protection for women. Thus, it is discussed other ways of protection associated with longevity in women. Of these, the sirtuin system was found in several animal studies to be associated with longevity. This system also showed, through the involvement of several metabolic pathways, an important protection against the process of atherosclerosis. But the activity of this system in humans is unknown and if it is more active in women than in men. The study's main objectives are to analyze this system in healthy 24 women and 24 men aged 55 to 65 years, and their influence on the main metabolic pathways related to longevity and the process of atherosclerosis. The research protocol includes analysis of the influence of sirtuin (SIRT1) in vascular reactivity, lipid profile, antioxidant capacity, markers of inflammation and homeostasis, before and after the interventions with caloric restriction or resveratrol administration. It is expected of this study mechanistic conclusion for longevity and possible clinical applications in the mechanism of atherosclerosis prevention.

Direct evaluation of the Sirtuin 1 levels [ Time Frame: 30 days ] [ Designated as safety issue: No ]

The Sirtuin 1 system will be measured through analysis of mRNA expression in periferic blood. This analysis will be done before and after the intervention with caloric restriction or resveratrol administration.

Secondary Outcome Measures:

Influence of the Sirtuin 1 system on biomarkers and endothelial function. [ Time Frame: 30 days ] [ Designated as safety issue: No ]

For indirect analysis of the situin 1 system, the following procedures will be done before and after the intervention with caloric restriction or resveratrol administration:

12 men will receive a pill with 500mg of resveratrol daily for 30 days

Drug: Resveratrol

1 pill daily containing 500 mg/d of resveratrol for 30 days

Other Name: resveratrol

Experimental: women with resveratrol

12 women will receive a pill with 500mg of resveratrol daily for 30 days

Drug: Resveratrol

1 pill daily containing 500 mg/d of resveratrol for 30 days

Other Name: resveratrol

Active Comparator: men with caloric restriction

12 men will follow a 1000kcal/day diet for 30 days

Behavioral: Caloric restriction

Diet of 1000kcal per day for 30 days

Active Comparator: women with caloric resctriction

12 women will follow a 1000kcal/day diet for 30 days

Behavioral: Caloric restriction

Diet of 1000kcal per day for 30 days

Detailed Description:

After a washout period of 15 days without medication, men and women will be randomized to the group of calorie restriction or resveratrol so that in 24 individuals (12 women and 12 men) will be given a hypocaloric diet (1000 calories per day) and the remaining 24 individuals (12 women and 12 men), a daily pill of 500mg of resveratrol. In the two moments, after the washout period and before the intervention (baseline) and after 30 days of intervention (final) will evaluate the clinical, laboratory and vascular reactivity of all subjetcs.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01668836